⁶⁸Ga-prostate-specific membrane antigen (PSMA) and ⁶⁸Ga-DOTA0-Tyr3-octreotate (DOTATATE) positron emission tomography/computed tomography (PET/CT) in a case of metastatic castration-resistant prostate cancer (mCRPC) with low prostate-specific antigen (PSA) and reduced ¹⁸F-fluorodeoxyglucose (FDG) uptake after endocrine therapy.

ABSTRACT:

SUBMITTER: Li L 

PROVIDER: S-EPMC12514692 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature